Octapharma USA launches new co-pay assistance program for eligible patients who use Wilate® to treat von Willebrand disease (VWD).
FDA accepts Bayer's Biologics License Application for new investigational recombinant FVIII therapy to treat hemophilia A in children and adults.
Record number of participants flock to DC for this year’s Washington Days advocacy event, February 25-27, 2015.
Progress made by Baxter during clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy.
NHF is excited to partner with chapters to deliver six Collaborating in Care educational modules, some of which are now available.
New recombinant factor VIIa therapy expected to extend half-life for people with hemophilia A or B with inhibitors.
New Biogen Idec global partnership to use lentiviral vectors in developing gene therapies for hemophilia A and B.
This chapter provides an overview of inhibitors, antibodies to factor product, including the causes and conditions underlying this complication.
Researchers use bio-engineered lettuce leaves to deliver high volumes of factor IX in dogs with hemophilia.
NHF Announces New Patient Brochure on Prolonged Half-Life Products.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car